Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-γ-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation

Blood

Volumn 99, Issue 10, 2002, Pages 3830-3837

  Hebart, Holger ^a   Daginik, Senay ^a   Stevanovic, Stefan ^a   Grigoleit, Ulrich ^a   Dobler, Andrea ^a   Baur, Manuela ^a   Rauser, Georg ^a   Sinzger, Christian ^a   Jahn, Gerhard ^a   Loeffler, Juergen ^a   Kanz, Lothar ^a   Rammensee, Hans Georg ^a   Einsele, Hermann ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; THIOTEPA;

ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CYTOMEGALOVIRUS; LEUKAPHERESIS; LEUKEMIA; MALE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 0037093102     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.10.3830     Document Type: Article

References (35)

1. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European Bone Marrow Transplant Group
2. PCR monitoring after BMT to reduce the incidence of CMV disease and the duration and side effects of antiviral therapy
3. Successful modification of a pp65 anti-genemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients
4. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
5. Lymphocyte responses after cytomegalovirus infection in bone marrow transplant recipients - A one-year follow-up
6. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
7. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
8. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease
9. T-cell epitope mapping by flow cytometry
10. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides
11. + T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens
12. + T cell frequencies by flow cytometry: Evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency
13. The human cytotoxic (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL
14. Development of a candidate HLA-A*0201 restricted peptide-based vaccine against human cytomegalovirus infection
15. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes
16. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus
17. Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells
18. Syfpeithi: Database for MHC ligands and peptide motifs
19. Peptides naturally presented by MHC class I molecules
20. + virus specific cytotoxic T lymphocytes
21. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
22. Her-2/neu derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
23. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
24. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
25. + dendritic cells
26. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: Reevaluation of prevalence of IE1-specific CTLs
27. + T cells produce antiviral cytokines but are impaired in cytolytic function
28. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis
29. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation
30. + T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection
31. Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses
32. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant
33. Minimal phenotype panels. A method for achieving maximum population coverage with a minimum of HLA antigens
34. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA tetramers